27)
Allavena P, et al.：Cancer Res., 65, 2964（2005）

28)
Germano G, et al.：Cancer Cell, 23, 249（2013）

29)
Forni C, et al.：Mol Cancer Ther., 8, 449（2009）

30)
Grohar PJ, et al.：Neoplasia, 13, 145（2011）

文献請求先

主要文献に記載の社内資料につきましても下記にご請求ください。

大鵬薬品工業株式会社　医薬品情報課

〒101-8444　東京都千代田区神田錦町1-27

TEL　0120-20-4527

FAX　03-3293-2451

製造販売業者等の氏名又は名称及び住所

製造販売元
大鵬薬品工業株式会社

東京都千代田区神田錦町1-27

提携先
Pharma Mar, S.A.

スペイン
New release of anticancer agent "Yondelis intravenous infusion" new release - Taiho Pharmaceutical
Acquired manufacturing and marketing approval based on indications of refractory malignant soft tissue tumor
On November 26, Taiho Pharmaceutical Co., Ltd. announced that the anticancer agent "Yondelis (R) 0.25 mg/1 mg for intravenous infusion" (generic name: Traveectein) was listed as a drug price. Release is scheduled for December 7.
It is an antineoplastic agent that was created by Pharmamar, Spain. Taiho Pharmaceutical Co., Ltd. signed a licensing agreement with Pharmama for development and marketing in Japan after development in 2009, and in September this year, acquired marketing approval with indications of "malignant soft tissue tumor" did.
Malignant soft tissue tumor is a refractory malignant tumor that develops in the soft tissues of the body (muscle, connective tissue, fat, blood vessel lymphatic vessels, etc.). The annual morbidity rate in Japan is about 2 to 3 people per 100,000 people, and it is said that it is a rare disease of about 5,000 estimated patients.
Established synthetic method with natural material isolated from a kind of ascidian
It is a natural product (an alkaloid compound having three tetrahydroisoquinoline rings) originally isolated from Ecteinascidia turbinata (Ecteinasidia · turbinata) of a squirrel of the Caribbean sea, and now it has established a synthetic method. It is a drug that binds to DNA and has an effect by interfering with cell division, gene transcription, DNA repair mechanisms.
In September 2007, it was approved in Europe for the efficacy and effect of "treatment of advanced malignant soft tissue tumors ineffective for anthracyclines and ifosfamide, or not suitable for administration of these drugs". In the world, it is approved in 78 countries and regions including the United States, Europe, South America, Asia, etc.
Taiho Pharmaceutical Industry expects that it will be one of new treatment options for malignant soft tissue tumors with high unmet / medical needs.